The Kratom Council

Latest / Regulation

Regulation

The 7-OH Comment Window Closes September 10 — And It Is Not The Thing That Decides The Ban

Two identical grey steel document trays side by side, the left holding a thick stack of plain paper and the right completely empty.

A federal comment docket on 7-hydroxymitragynine closes on September 10. In the ten days remaining, this publication has seen the deadline described in industry and advocacy channels as a last chance to stop a ban. That is not what it is, and the difference matters to anyone deciding whether to spend time on it.

What follows is an attempt to set out plainly what is open, what it decides, what it does not decide, and how the two federal tracks running in parallel actually relate to one another.

Two Agencies, Two Tracks, One Compound

The confusion is structural, and it is understandable. Two different parts of the federal government are working on 7-OH at the same time, under different authorities, on different clocks.

The Drug Enforcement Administration holds the scheduling authority. On July 6 it published a notice of intent to place 7-hydroxymitragynine above a specified threshold into Schedule I on a temporary basis. That notice stated the order would not publish before August 5. The thirty-day statutory minimum elapsed on that date. As of this publication's most recent verified check, the final order has still not issued — but it can publish on any day, without further warning, and would take effect on publication.

The Department of Health and Human Services, through the Office of the Assistant Secretary for Health, opened a separate public docket on the same day: a request for information on the proposed threshold itself. That docket, HHS-OASH-2026-0232, is the one closing September 10.

The two are related but not sequenced. Nothing in either document states that the DEA order waits on the HHS docket, and this publication has found no basis in the public record for the assumption that it does. The comment window closing on September 10 does not create a date on which the order issues, and the order issuing would not, by itself, close the docket. Readers planning around either date should hold both loosely.

What The Docket Actually Asks

The question in front of HHS is narrower than "should 7-OH be banned," and the narrowness is the point.

The DEA's proposal does not reach 7-OH at any concentration. It reaches material above a line: botanical material of Mitragyna speciosa containing more than 0.050 percent 7-hydroxymitragynine on a dry weight basis, and processed articles containing more than 1.00 milligram of 7-OH. The HHS docket solicits input on that threshold — whether the number is set in the right place, and what evidence bears on it.

That framing is why the threshold exists at all. Published analyses place naturally occurring 7-OH in kratom leaf below the 0.050 percent line, and the Food and Drug Administration has stated the proposal is “not intended to apply to natural kratom leaf containing only naturally occurring trace levels of 7-OH.” The line is the mechanism by which federal policy separates the leaf from concentrated and synthesized material. A comment arguing about where that line sits is responsive to what was asked. A comment arguing that kratom should or should not be legal is, procedurally speaking, addressed to a question the docket did not pose.

What Is Already In The Record

The first round was not quiet. The original thirty-day window closed July 31 having drawn more than 32,000 comments, by figures reported in trade and advocacy coverage. This publication has not been able to open regulations.gov directly to confirm the count against the docket itself, and states it here as reported rather than verified.

OASH then extended the window by fifteen days, producing the September 10 deadline. The extension notice published August 26 — the same morning the DEA's separate order on mitragynine pseudoindoxyl, MGM-15 and MGM-16 took effect. Neither document explains the timing of the other, and this publication declines to infer a relationship the record does not state.

What the volume does establish is that the threshold question has already been heavily commented on. A docket that has drawn tens of thousands of submissions is not one where a marginal comment carries much individual weight, and anyone deciding how to spend the next ten days should factor that in honestly.

How The Mechanism Works

Comments are submitted through regulations.gov, on the docket page for HHS-OASH-2026-0232. Submissions are part of a public record: filings are generally posted publicly, including any identifying information a submitter chooses to include, and cannot be reliably withdrawn once made. Anyone commenting in a business capacity should weigh that before filing.

An agency is obliged to consider material submitted to a docket it opened. It is not obliged to agree, to respond individually, or to change course because of submission volume. Dockets are not votes, and a comment's influence tends to track what it contains rather than that it exists — testing data, analytical methodology, or documented commercial consequence of a particular number are the kinds of material a threshold docket is built to receive.

What This Publication Is Not Saying

This report takes no position on whether anyone should comment, or on what a comment should say. The Kratom Council does not run advocacy campaigns and is not organizing one here. Its interest in the deadline is that readers of a kratom news publication should know what a federal docket is for before deciding whether it is worth their time, and should not be told a procedural window is a referendum.

Nor does anything here predict where the threshold lands, or when. The proposal is a proposal. The order has not issued. The comment window closes September 10 either way.

The Dates That Matter

September 10, 2026: the HHS comment docket on the 7-OH threshold closes. Pending, with no announced date: the DEA's temporary scheduling order on 7-OH above the threshold, which can publish on any day and takes effect on publication. Already in force since August 26 and unaffected by either: the Schedule I placement of mitragynine pseudoindoxyl, MGM-15 and MGM-16, which carries no threshold at all. Unchanged by any current federal action: natural kratom leaf, which remains subject to state law that varies considerably and is worth checking locally.

Sources

  1. Federal Register — HHS/OASH, "Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I; Request for Information," Docket No. HHS-OASH-2026-0232 (July 6, 2026)
  2. Federal Register — HHS/OASH, extension of comment period to September 10, 2026 (August 26, 2026)
  3. Regulations.gov — Docket HHS-OASH-2026-0232
  4. Federal Register — DEA notice of intent on 7-hydroxymitragynine above a specified threshold, Docket No. DEA-1570 (July 6, 2026)
  5. Federal Register — temporary scheduling order, mitragynine pseudoindoxyl, MGM-15 and MGM-16, Docket No. DEA-1644 (published and effective August 26, 2026)
  6. The Kratom Council — "The Council Answers: What The August 26 Scheduling Order Actually Covers — And What It Does Not" (August 30, 2026)
  7. The Kratom Council — "The Federal Comment Window On 7-OH Has Closed. The Order Can Issue Any Time After August 5." (August 3, 2026)
  8. The Kratom Council — "DEA Schedules Three 7-OH Analogs. The 7-OH Threshold Order Itself Still Has Not Issued." (August 26, 2026)

← Back to all coverage

Get new reporting by email